Outcomes of Dorsiflexion Closing Wedge Osteotomy for Freiberg Disease with Large Lesions: A Multicenter Retrospective Study
- 1Orthopedic Surgery Department, Faculty of Medicine, Capital University, Cairo, Egypt.
- 2Orthopedic Surgery Department, Faculty of Medicine, Capital University, Cairo, Egypt
- 3Orthopedic Surgery Department, Faculty of Medicine, Benha University, Benha, Egypt
Abstract
Background: While osteochondral autologous transplantation is favoured for Freiberg disease with large lesions, dorsiflexion closing wedge metatarsal osteotomy (DCWMO) remains a joint-preserving alternative. Objectives: To evaluate the clinical and functional outcomes of DCWMO for large-lesion Freiberg disease. Methods: This retrospective multicentre cohort study included 12 patients with Freiberg disease treated with extra-articular DCWMO between January 2019 and June 2025. Functional outcomes were assessed. Follow-up extended to a median of 4 years (8 months–7 years). Results: Significant postoperative improvements were observed: median MTPJ plantarflexion increased from 10° to 35° (P=0.002), dorsiflexion from 30° to 50° (P=0.002), and Visual Analog Scale pain scores declined from 9 to 1 (P=0.002). JSSF scores rose from 72 ± 8 to 95 ± 3 (P<0.001), and FADI scores from 68 ± 10 to 97 ± 3 (P<0.001). Conclusions: DCWMO offered a reliable, cost-effective, and biologically conservative solution for managing Freiberg disease, achieving durable improvements in pain, range of motion, and function.
Related
- Risk factors for surgical site infection requiring reoperation after osteotomy around the knee: a multicenter retrospective study.
- Association Between Postoperative Mechanical Alignment and Clinical Outcomes After Medial Opening-Wedge High Tibial Osteotomy: A Retrospective Cohort Study
- Irreparable Posterosuperior Rotator Cuff Tears Treated With InSpace Balloon With or Without Arthroscopic Subscapularis Repair: Short‐Term Clinical Outcomes in a Multicenter Retrospective Study
- Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study
- Clinical outcomes of near-infrared photoimmunotherapy according to immune checkpoint inhibitor timing and treatment sequence: a multicenter retrospective study
BibTeX
@article{amer2026outcomes,
title = {{Outcomes of Dorsiflexion Closing Wedge Osteotomy for Freiberg Disease with Large Lesions: A Multicenter Retrospective Study}},
author = {Ahmed Ramy Zakaria Amer and Mohamed Rabie Abdallah Saleh and Mahmoud Abou Zied},
journal = {The Egyptian Orthopaedic Journal},
year = {2026},
month = oct,
doi = {10.21608/eoj.2026.525328.1259},
url = {https://doi.org/10.21608/eoj.2026.525328.1259},
note = {CC BY},
}
RIS
TY - JOUR
TI - Outcomes of Dorsiflexion Closing Wedge Osteotomy for Freiberg Disease with Large Lesions: A Multicenter Retrospective Study
AU - Ahmed Ramy Zakaria Amer
AU - Mohamed Rabie Abdallah Saleh
AU - Mahmoud Abou Zied
PY - 2026
DA - 2026/10/25
JO - The Egyptian Orthopaedic Journal
DO - 10.21608/eoj.2026.525328.1259
UR - https://doi.org/10.21608/eoj.2026.525328.1259
AB - Background: While osteochondral autologous transplantation is favoured for Freiberg disease with large lesions, dorsiflexion closing wedge metatarsal osteotomy (DCWMO) remains a joint-preserving alternative. Objectives: To evaluate the clinical and functional outcomes of DCWMO for large-lesion Freiberg disease. Methods: This retrospective multicentre cohort study included 12 patients with Freiberg disease treated with extra-articular DCWMO between January 2019 and June 2025. Functional outcomes were assessed. Follow-up extended to a median of 4 years (8 months–7 years). Results: Significant postoperative improvements were observed: median MTPJ plantarflexion increased from 10° to 35° (P=0.002), dorsiflexion from 30° to 50° (P=0.002), and Visual Analog Scale pain scores declined from 9 to 1 (P=0.002). JSSF scores rose from 72 ± 8 to 95 ± 3 (P<0.001), and FADI scores from 68 ± 10 to 97 ± 3 (P<0.001). Conclusions: DCWMO offered a reliable, cost-effective, and biologically conservative solution for managing Freiberg disease, achieving durable improvements in pain, range of motion, and function.
SN - 2090-9926
SN - 1110-1148
ER -